Insulin glargine provides basal insulin requirements in the management of diabetes mellitus

被引:0
|
作者
不详
机构
关键词
Insulin Glargine; Insulin Lispro; Injection Site Reaction; Tight Glycaemic Control; Receive Insulin Glargine;
D O I
10.2165/00042310-200218070-00003
中图分类号
学科分类号
摘要
Insulin therapy is essential for patients with type 1 (insulin-dependent) diabetes mellitus. It also has an important role in those with type 2 (non-insulin-dependent) diabetes mellitus when diet and oral antidiabetic agents have proved inadequate. Intensive insulin therapy has been shown to provide tight control of blood glucose levels in patients with diabetes mellitus, thus reducing the risk of microvascular and macrovascular complications. However, there is also an associated risk of hypoglycaemia. Insulin glargine is an insulin analogue which provides basal insulin requirements as part of a basal-bolus regimen. As it precipitates in the neutral pH of subcutaneous (SC) tissue after injection, insulin glargine has delayed absorption and a prolonged duration of action (22 hours). In addition, insulin glargine essentially has no peak effect. Once daily insulin glargine appears to be at least as effective at reducing fasting blood glucose (FBG) levels as Neutral Protamine Hagedorn (NPH) insulin. Importantly, hypoglycaemia occurs less often with insulin glargine than with NPH insulin. Insulin glargine is well tolerated. Injection site reactions are common, but are typically mild.
引用
收藏
页码:7 / 9
页数:2
相关论文
共 50 条
  • [1] A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
    Riccardo Candido
    Kathleen Wyne
    Ester Romoli
    [J]. Diabetes Therapy, 2018, 9 : 927 - 949
  • [2] A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
    Candido, Riccardo
    Wyne, Kathleen
    Romoli, Ester
    [J]. DIABETES THERAPY, 2018, 9 (03) : 927 - 949
  • [3] Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus
    Clements, Jennifer N.
    Bello, Larkin
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (06) : 359 - 366
  • [4] Intensified insulin therapy of type 2 diabetes mellitus: Insulin glargine vs. insulin detemir as basal insulin
    Jungmann, Eckart
    [J]. DIABETES, 2006, 55 : A118 - A118
  • [5] Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus: Using insulin glargine as basal insulin
    Kawamori, Ryuzo
    Kadowaki, Takashi
    Ishii, Hitoshi
    Iwasaki, Manabu
    Iwamoto, Yasuhiko
    [J]. DIABETES, 2008, 57 : A573 - A573
  • [6] The utility of insulin glargine in the treatment of diabetes mellitus
    Stroup, J
    Kane, MP
    Busch, RS
    Bakst, G
    Hamilton, RA
    [J]. PHARMACOTHERAPY, 2004, 24 (06): : 736 - 742
  • [7] Insulin glargine - An updated review of its use in the management of diabetes mellitus
    Dunn, CJ
    Plosker, GL
    Keating, GM
    McKeage, K
    Scott, LJ
    [J]. DRUGS, 2003, 63 (16) : 1743 - 1778
  • [8] Use of insulin glargine in dogs with diabetes mellitus
    Fracassi, F.
    Boretti, F. S.
    Sieber-Ruckstuhl, N. S.
    Reusch, C. E.
    [J]. VETERINARY RECORD, 2012, 170 (02) : 52 - U107
  • [9] Insulin glargine treatment of a ferret with diabetes mellitus
    Hess, Laurie
    [J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2012, 241 (11): : 1490 - 1494
  • [10] The use of insulin glargine with gestational diabetes mellitus
    Graves, DE
    White, JC
    Kirk, JK
    [J]. DIABETES CARE, 2006, 29 (02) : 471 - 472